Search for: "Sanofi"
Results 21 - 40
of 1,197
Sort by Relevance
|
Sort by Date
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
6 Mar 2024, 10:15 am
Sanofi Pasteur Inc. affirming lower rulings by the Patent Trial and Appeal Board (PTAB) that invalidated Pfizer’s patent claims and denied motions to amend (MTA). [read post]
6 Mar 2024, 10:15 am
Sanofi Pasteur Inc. affirming lower rulings by the Patent Trial and Appeal Board (PTAB) that invalidated Pfizer’s patent claims and denied motions to amend (MTA). [read post]
5 Mar 2024, 10:55 am
., Adventist Health System, a 340B covered entity, is suing pharmaceutical manufacturers AbbVie, AstraZeneca, Novartis, Sanofi, and Sandoz alleging that the manufacturers caused violations of the False Claims Act and various state anti-fraud laws when calculating the 340B price for drugs with price increases that outpaced inflation. [read post]
5 Mar 2024, 10:23 am
Sanofi Opinion. [read post]
23 Jan 2024, 9:01 pm
2023 delivered a banner year for investor recoveries, as the $7.9 billion[1] in settlement funds across the globe was the highest total in the last five years. [read post]
21 Jan 2024, 9:01 pm
Many of these cases have important implications for near-term merger reviews and enforcement actions including Sanofi/Maze Therapeutics (abandoned), a challenge to the license of a phase 2-ready pharmaceutical, traditionally viewed as likely too nascent to present a competitive issue; Amgen/Horizon Therapeutics (consent decree), a challenge focused on the parties’ ability to entrench the existing monopoly position of a non-overlap product; and Anesthesia Partners (ongoing), as… [read post]
18 Jan 2024, 5:14 pm
Sanofi et al. [read post]
11 Jan 2024, 9:31 pm
Sanofi. [read post]
11 Jan 2024, 12:59 pm
Sanofi, 143 S. [read post]
9 Jan 2024, 3:30 pm
Sanofi. [read post]
9 Jan 2024, 3:30 pm
Sanofi. [read post]
9 Jan 2024, 1:15 pm
Sanofi the Supreme Court spoke. [read post]
9 Jan 2024, 1:15 pm
Sanofi the Supreme Court spoke. [read post]
31 Dec 2023, 4:29 pm
Sanofi In this case, the Supreme Court considered the validity of certain patents on antibodies used to lower cholesterol under the Patent Act’s enablement requirement (35 U.S.C. 112(a)). [read post]
29 Dec 2023, 4:00 am
Sanofi U.S. [read post]
27 Dec 2023, 5:51 am
Firstly, in the Amgen v Sanofi case, the well-publicized woes of the CMS on day one saw the parties competing for who could get their hard copy filing before the Court first. [read post]
22 Dec 2023, 5:29 am
PatKat reviewing the yearIt is time once more for the IPKat patent year in review! [read post]
